Chris Pepper, PhD

Brighton and Sussex Medical School, United Kingdom

N/A

Poster(s):

• 1010 - Toll-like receptor 9 signalling is a potential tumour escape mechanism following B-cell receptor targeted treatments in subsets of patients with Chronic Lymphocytic Leukaemia.

• 1121 - High-risk molecular features eclipse genomic complexity in predicting CLL patient outcomes; Insights from the UK CLL4, ARCTIC and ADMIRE trials.

• 1301 - Selective NIK Inhibition Overcomes Microenvironment-Mediated Resistance and Synergizes with Venetoclax in CLL

• 1310 - Evaluation of two novel Cyclin Dependent Kinase 9 inhibitors for the treatment of Myeloid Cell Leukaemia 1 (MCL1) high Chronic Lymphocytic Leukaemia

• 1311 - Targeted Degradation of NF-κB RelA/p65 by PBD-Based PROTACs as a Novel Therapeutic Strategy in Chronic Lymphocytic Leukaemia